Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has appointed Fred Hassan, a distinguished industry leader, to its board of directors, strengthening its leadership team as the company approaches dosing of patients in phase 3 pivotal trials of Duravyu in wet age-related macular degeneration (AMD) in 2024. Hassan, with extensive global biopharmaceutical experience, brings valuable analytical and strategic insights to the company.
The company also announced the resignation of Anthony P. Adamis, M.D. and David Guyer, M.D. from their positions as directors on the company’s board due to their transition to full-time roles at Merck & Co. The board expressed its gratitude for their outstanding service and contributions to Eyepoint, acknowledging the beneficial impact of their substantial industry insight and experience.
Eyepoint Pharmaceuticals is currently focused on developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The company's lead product candidate, Duravyu (formerly EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases. It combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Duravyu is currently in phase 2 clinical trials as a sustained delivery treatment for wet AMD and diabetic macular edema (DME), with plans to randomize patients for inclusion in pivotal phase 3 clinical trials for wet AMD in 2024. Additionally, the pipeline programs include EYP-2301, a tie-2 agonist, razuprotafib, formulated in Durasert E, aimed at potentially improving outcomes in serious retinal diseases.
Eyepoint Pharmaceuticals, headquartered in Watertown, Massachusetts, leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The proven Durasert drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products.
Vorolanib is licensed to Eyepoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. Duravyu has been conditionally accepted by the FDA as the proprietary name for EYP-1901, and it is an investigational product that has not been approved by the FDA. The approval and the timeline for potential approval are uncertain. The market has reacted to these announcements by moving the company's shares -8.9% to a price of $8.15. For the full picture, make sure to review EyePoint Pharmaceuticals's 8-K report.
